TG Therapeutics Inc (NASDAQ:TGTX) announced the presentation of updated clinical results from its ongoing Phase I single agent study of TGR-1202, the Company’s …
Stifel and FBR Capital analysts came out today with new ratings and price targets on a handful of healthcare stocks. Lets take a look …
TG Therapeutics Inc (NASDAQ:TGTX) announced its financial results for the third quarter ended September 30, 2015 and recent company developments. Michael S.
TG Therapeutics Inc (NASDAQ:TGTX) announced that updated data for TG-1101 (ublituximab), the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, the Company’s next generation …
Analysts are weighing in on the clinical biopharmaceutical company Mast Therapeutics Inc (NYSEMKT:MSTX) and development stage company TG Therapeutics Inc (NASDAQ:TGTX), with positive ratings and views. …
In a research report released yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on shares of TG Therapeutics Inc (NASDAQ:TGTX) with a …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of TG Therapeutics Inc (NASDAQ:TGTX) with a …
TG Therapeutics Inc (NASDAQ:TGTX) announced the initiation of a Phase 1/2 clinical study that will investigate the use of TGR-1202, the Company’s oral PI3K …
Earlier today, Brean Capital’s healthcare analyst Jonathan Aschoff weighed in with research reports on the DNA product development company Inovio Pharmaceuticals Inc (NASDAQ:INO), Biopharmaceutical company Repros Therapeutics Inc (NASDAQ:RPRX), …
TG Therapeutics Inc (NASDAQ:TGTX) announced its financial results for the second quarter ended June 30, 2015 and recent company developments. Michael S.
